Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments

Clinical & Experimental Allergy, 04/27/2012

New macrolides have been developed which do not possess any antimicrobial activity and hence lack the ability to produce microbial resistance, but which still retain immunomodulatory effects. Potentially novel macrolides may overcome a significant barrier to the use of this type of drug for the long–term treatment of chronic inflammatory airway diseases.

Go to PubMed Go to Abstract Print Article Summary